Fenwick & West represented BioAge Labs in the transaction. BioAge Labs (BioAge) announced it completed the oversubscribed $170M Series D financing round led by Sofinnova Investments...
BioAge’s $170 Million Series D Financing Round
Eyconis’ Formation and Launch
Fenwick & West represented Eychonis, Inc. in the transaction. Eyconis, Inc. announced their formation and $150 million capital raise. Eyconis was formed and launched by Ascendis...
Eli Lilly’s $2.4 Billion Pending Acquisition of DICE THerapeutics
Fenwick & West LLP represented DICE Therapeutics, Inc. in the transaction, while Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY)...
Abdera’s $142 Million Financing
Fenwick represented Abdera Therapeutics on the deal. Abdera Therapeutics, a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals...
Perceive Bio’s $78 Million Series B Financing
Fenwick represented Perceive Bio on the deal. Perceive Bio, a biotech company pioneering novel technologies and therapeutics in ophthalmology, announced its $78 million Series B financing. The...
Metagenomi’s $100 Million Series B Extension Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
Cleerly’s $192 Million Series C Financing
Fenwick represented Cleerly on the deal. Cleerly, a company creating a new standard of care for heart disease, announced its $192 million Series C financing. This new...
Melinta Therapeutics’ Acquisition of U.S. Rights to TOPROL-XL from New American Therapeutics
Fenwick advised Melinta Therapeutics on the deal. Melinta Therapeutics, a company providing innovative therapies for acute and life-threatening illnesses, announced its acquisition of the U.S. rights to...
Endpoint Health’s Collaboration with Grifols
Fenwick represented Endpoint Health on the deal. Endpoint Health, Inc., a precision-first™ therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, announced a...
Lyra Health’s $235 Million Financing
Fenwick & West advised Lyra Health on the deal. Lyra Health, a leading provider of innovative Workforce Mental Health solutions for employers, announced its $235 million financing....
Metagenomi’s $175 Million Series B Financing
Fenwick & West and Wilson Sonsini Goodrich & Rosati advised Metagenomi on the deal while Gunderson Dettmer represented PFM Health Sciences. Metagenomi, a genetic medicines company...
Castlight Health’s $370 Million Combination with Vera Whole Health
Fenwick & West advised Castlight Health on the deal, while Kirkland & Ellis advised Vera Whole Health. Castlight Health (NYSE: CSLT), a leading healthcare data and...